🧾 What This Document Is

This is Kura Oncology's Definitive Proxy Statement (DEF 14A). Think of it as the official "menu" and instruction manual for the company's upcoming annual shareholder meeting. It details what shareholders will vote on, provides background on the people running the company, and explains executive pay. Shareholders receive this to make informed voting decisions.

🏢 What The Company Does

👉 In simple terms, Kura Oncology is a cancer-focused biopharmaceutical company. They are in the business of discovering and developing new medicines for blood cancers (like leukemias and lymphomas). As a clinical-stage company, their products are still being tested in trials and are not yet approved for sale.

📅 Key Meeting Details

• Date & Time: Thursday, June 4, 2026, at 8:30 a.m. Pacific Time.
• Format: Virtual-Only Meeting. You can't attend in person. You'll join via a live webcast at www.proxydocs.com/KURA.
• Record Date: April 6, 2026. Only shareholders owning stock on this date can vote.
• Shares Outstanding: 88,762,704 shares eligible to vote.
• Quorum Needed: At least 44,381,353 shares must be present (virtually or by proxy) for the meeting to be valid.

🗳️ What You're Voting On (The Proposals)

The Board recommends voting "FOR" on all proposals. Here’s the lineup:

#	Proposal	What It Means	Why It Matters
1	Elect 3 Directors	Vote to re-elect Diane Parks, Mary Szela, and Michael Vasconcelles to the board.	These individuals will help steer the company's strategy and oversee management.
2	Ratify Auditor	Approve Ernst & Young LLP as the company's accountant for 2026.	A routine but essential check on the company's financial reporting.
3	Say-on-Pay	Advisory vote to approve executive compensation.	Your chance to signal approval or disapproval of how top leaders are paid.
4	Say-on-Pay Frequency	Vote on how often to hold the "Say-on-Pay" vote (every 1, 2, or 3 years).	The Board recommends "1 Year" (annual votes).
5	Amend 2014 Equity Plan	Increase the number of shares available to grant as stock options/awards to employees & directors.	A bigger "pool" helps attract and retain talent in a competitive field.
6	Amend 2015 ESPP	Increase shares available for the Employee Stock Purchase Plan.	Allows more employees to buy company stock at a discount.

Why it matters: Proposals 3-6 are where shareholder influence is most direct. The equity plan votes (5 & 6) are crucial because they involve dilution—creating more shares, which can reduce the value of your existing shares if the company doesn't grow correspondingly.

👥 Meet the Director Nominees (Proposal 1)

The company highlights the specific skills they bring. Here’s a snapshot:

• Diane Parks (73): Expert in launching cancer drugs commercially (e.g., Yescarta, Imbruvica).
• Mary T. Szela (62): Experienced CEO with deep knowledge of pharmaceutical operations and strategy.
• Michael J. Vasconcelles, M.D. (62): Brings deep R&D and medical expertise, having led clinical development at major companies like ImmunoGen and Takeda.

👉 Why it matters: The board is stacking itself with commercial launch experience (Parks), operational leadership (Szela), and deep clinical R&D knowledge (Vasconcelles)—all critical for a biotech aiming to bring a new cancer drug to market.

💼 Executive Compensation & Governance

This section details how much the top executives are paid and the board's structure.

• Say-on-Pay (Proposal 3): You'll see a "Summary Compensation Table" later detailing salary, bonuses, and stock awards for the CEO and other top officers.
• Board Independence: All directors except CEO Troy Wilson are deemed "independent."
• Lead Independent Director: Faheem Hasnain serves this role, providing independent leadership on the board.
• Board Committees: Key committees are Audit (chaired by Carol Schafer), Compensation (chaired by Mary Szela), and Nominating/Governance (chaired by Thomas Malley).

💸 The Equity Plan Amendments (Proposals 5 & 6)

These are significant because they ask you to approve more shares for compensation.

• 2014 Equity Incentive Plan (Proposal 5): Seeks to add 3,000,000 new shares to the plan. This is the primary tool for granting stock options and awards to retain key scientific and management talent.
• 2015 Employee Stock Purchase Plan (Proposal 6): Seeks to add 1,000,000 new shares. Allows employees to buy Kura stock at a 15% discount.

Why it matters: In biotech, equity is a major part of compensation. A larger share pool is seen as necessary to hire top talent, but it does dilute existing shareholders. The company is arguing this is essential for its growth and drug development mission.

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths (from the filing): Experienced board with commercial, operational, and R&D expertise. Clear governance structure with independent directors. Commitment to employee development and corporate responsibility.
• ⚠️ Risks to Consider: As a clinical-stage biotech, Kura has no approved products or revenue from sales. Its success is entirely dependent on the costly and risky development of its drug pipeline. The proposals to increase equity compensation highlight the need to retain talent in this high-stakes, competitive field.

🧠 The Analogy

Voting on this proxy is like being a part-owner reviewing the report card and budget for a high-potential but unproven sports team. You're voting on the coaches (directors), the team's financial auditor, how the star players (executives) are paid, and whether to allocate more of the team's budget (shares) to signing bonuses (equity plans) to keep the best talent—all while the team is still in training (clinical trials) and hasn't won a championship (gotten a drug approved) yet.

🧩 Final Takeaway

This proxy is about maintaining the team and resources Kura Oncology believes it needs to achieve its goal of developing cancer drugs. Your vote directly influences the company's leadership, oversight, and its strategy for compensating and incentivizing the people tasked with executing that high-risk, high-reward mission.